Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.
胰高血糖素樣肽-1 受體激動劑在阿茲海默症和帕金森氏症中的角色。
J Biomed Sci 2024-11-05
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
GLP-1類藥物在帕金森病和阿茲海默症臨床試驗中展現明顯的保護效果:一場革命正在醞釀中?
Neuropharmacology 2024-05-18
Type 2 diabetes mellitus/obesity drugs: a neurodegenerative disorders savior or a bridge too far?
第二型糖尿病/肥胖藥物:神經退行性疾病的救星還是一步太遠?
Ageing Res Rev 2024-05-18
Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study.
GLP-1 受體激動劑在神經退行性疾病中的神經保護作用:一項大規模傾向匹配隊列研究。
Int Immunopharmacol 2024-11-01
The mechanism and related research progress of GLP-1 receptor agonists in treating Alzheimer's disease.
GLP-1 受體激動劑在治療阿茲海默症中的機制及相關研究進展。
Yi Chuan 2024-12-11
GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.
GLP-1 受體激動劑作為帕金森病發展中的潛在神經調節劑:一項全國性隊列研究。
Eur J Neurol 2025-02-10
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
GLP-1 受體激動劑,我們是否見證了神經-心臟-代謝疾病的範式轉變?
Pharmacol Ther 2025-02-21